Vivo Capital
Venture Capital, Private equity
Active
Palo Alto, United States
220
61M
152
7.86
31
0.31
89
- Stages of investment
- Areas of investment
Summary
In 1997 was created Vivo Capital, which is appeared as VC. The venture was found in North America in United States. The main office of represented VC is situated in the Palo Alto.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vivo Capital, startups are often financed by Sofinnova Investments, OrbiMed, Third Rock Ventures. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Frazier Healthcare Partners, Aisling Capital. In the next rounds fund is usually obtained by Sofinnova Investments, Aisling Capital, Technology Partners.
The fund has exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline ZAI Lab, Harmony Biosciences, Passage Bio Among the most popular fund investment industries, there are Medical, Genetics.
This organization was formed by Edgar G. Engleman. The overall number of key employees were 11.
Comparing to the other companies, this Vivo Capital performs on 11 percentage points more the average number of lead investments. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Vivo Capital the average startup value is 100-500 millions dollars. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The higher amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.
Investor highlights
- Industry focus
- Stage focus
- Geo focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 220
- Lead investments
- 31
- Exits
- 89
- Rounds per year
- 7.86
- Follow on index
- 0.31
- Investments by industry
- Biotechnology (165)
- Health Care (132)
- Pharmaceutical (89)
- Therapeutics (70)
- Medical (69) Show 56 more
- Investments by region
-
- United States (172)
- China (30)
- United Kingdom (7)
- Singapore (2)
- France (1) Show 6 more
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 9
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 73M
- Group Appearance index
- 0.95
- Avg. company exit year
- 10
- Avg. multiplicator
- 3.35
- Strategy success index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Ajax Therapeutics | 13 May 2024 | Biotechnology, Medical, Life Science | Late Stage Venture | 95M | United States, Massachusetts, Cambridge |
EpiBiologics | 20 Jul 2023 | Biotechnology, Health Care, Medical, Therapeutics | Early Stage Venture | 23M | United States, California, San Mateo |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.